Impaired Cardiometabolic Responses to Glucagon-Like Peptide 1 in Obesity and Type 2 Diabetes Mellitus

Basic Research in Cardiology - Germany
doi 10.1007/s00395-013-0365-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Glucagon-Like Peptide Analogues for Type 2 Diabetes Mellitus

2007English

Glucagon-Like Peptide 1 Receptor Agonists: A New Approach to Type 2 Diabetes Management

South African Family Practice
2013English

Correction To: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features

Clinical Drug Investigation
MedicinePharmacology
2020English

Comparison of Obesity Related Cardiometabolic Risks in Diabetes Type 1 and 2

Russian Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

Obesity and Type 2 Diabetes Mellitus

Internal Medicine: Open Access
2014English

Obesity and Type 2 Diabetes Mellitus

Integrative Obesity and Diabetes
2018English

Glucagon-Like Peptide-1 Analogues and Anxiety and Abnormal Eating Behaviours in Type 2 Diabetes: A Case Report

Journal of Diabetes & Metabolism
2014English

Magnitude and Variability of the Glucagon-Like Peptide-1 Response in Patients With Type 2 Diabetes Up to 2 Years Following Gastric Bypass Surgery

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2011English

Review of Glucagon‐Like Peptide‐1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in Patients With Chronic Kidney Disease and Their Renal Effects

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy